New approaches to the concept of primary prevention of atherosclerosis

Current Treatment Options in Cardiovascular Medicine

Volumn 10, Issue 1, 2008, Pages 73-82

  Ford, Monique A ^b   Allison, Thomas G ^b   Lerman, Amir ^a  

^a Mayo Clinic   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; FENOFIBRATE; FIBRINOGEN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; MK 0524A; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHOLIPASE A2; PIOGLITAZONE; PROSTAGLANDIN D2 INHIBITOR; PROSTAGLANDIN INHIBITOR; RECOMBINANT APOLIPIPOROTEIN A1 MILANO; ROSIGLITAZONE; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DRUG FATALITY; DRUG MECHANISM; DRUG SCREENING; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEMATOPOIETIC STEM CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MATERNAL DISEASE; MEDITERRANEAN DIET; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME; STEM CELL; VASA VASORUM; VASCULITIS; VIRUS INFECTION;

EID: 39049161649     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-008-0008-y     Document Type: Review

References (61)

1. Khot UN, Khot MB, Bajzer CT, et al.: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898-904.
2. Napoli C, Lerman LO, de Nigris F, et al.: Rethinking primary prevention of atherosclerosis-related diseases. Circulation 2006, 114:2517-2527.
3. Libby P.: Bone marrow: a fountain of vascular youth? Circulation 2003, 108:378-379.
4. Deanfield JE, Halcox JP, Rabelink TJ: Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007, 115:1285-1295
5. Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003, 23:168-175.
6. Lerman A, Burnett JC Jr, Higano ST, et al.: Long-term l-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998, 97:2123-2128.
7. Libby P, Ridker PM: Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004, 116(Suppl 6A):9S-16S.
8. de Nooijer R, Verkleij CJ, von der Thusen JH, et al.: Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 2006, 26:340-346.
9. Doyle B, Caplice N: Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 2007, 49:2073-2080.
10. Tziakas DN, Kaski JC, Chalikias GK, et al.: Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J Am Coll Cardiol 2007, 49:2081-2089.
11. Kolodgie FD, Narula J, Yuan C, et al.: Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy? J Am Coll Cardiol 2007, 49:2093-2101.
12. Shantsila E, Watson T, Lip GY: Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007, 49:741-752.
13. Shamsuzzaman AS, Gersh BJ, Somers VK: Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003, 290:1906-1914.
14. Reichmuth KJ, Austin D, Skatrud JB, Young T: Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med 2005, 172:1590-1595.
15. Yaggi HK, Concato J, Kernan WN, et al.: Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005, 353:2034-2041.
16. Kato M, Roberts-Thomson P, Phillips BG, et al.: Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 2000, 102:2607-2610.
17. Montorsi P, Ravagnani PM, Galli S, et al.: Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient. Eur Urol 2006, 50:721-731.
18. Baker WL, Couch KA: Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis. Am J Health Syst Pharm 2007, 64:830-836.
19. D'Aiuto F, Parkar M, Nibali L, et al.: Periodontal infections cause changes in traditional and novel cardiovascular risk factors: results from a randomized cçntrolled clinical trial. Am Heart J 2006, 151:977-984.
20. Grahame-Clarke C: Human cytomegalovirus, endothelial function and atherosclerosis. Herpes 2005, 12:42-45.
21. de Boer OJ, Teeling P, Idu MM, et al.: Epstein Barr virus specific T-cells generated from unstable human atherosclerotic lesions: implications for plaque inflammation. Atherosclerosis 2006, 184:322-329.
22. Stary HC: Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989, 9:119-132.
23. Palinski W, Napoli C: The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J 2002, 16:1348-1360.
24. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
25. Ridker PM: C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007, 49:2129-2138.
26. Ridker PM, Morrow DA, Rose LM, et al.: Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005, 45:1644-1648.
27. Morrow DA, de Lemos JA, Sabatine MS, et al.: Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006, 114:281-288.
28. Ridker PM: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003, 108:2292-2297.
29. Pepys MB, Hirschfield GM, Tennent GA, et al.: Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006, 440:1217-1221.
30. Danesh J, Lewington S, Thompson SG, et al.: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294:1799-1809.
31. Meuwese MC, Stroes ES, Hazen SL, et al.: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 50:159-165.
32. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022.
33. Yang EH, McConnell JP, Lennon RJ, et al.: Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006, 26:106-111.
34. Lavi S, McConnell JP, Rihal CS, et al.: Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007, 115:2715-2721.
35. Garza CA, Montori VM, McConnell JP, et al.: Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007, 82:159-165.
36. Ballantyne C, Cushman M, Psaty B, et al.: Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2007, 14:3-11.
37. Kullo IJ, Ballantyne CM: Conditional risk factors for atherosclerosis. Mayo Clin Proc 2005, 80:219-230.
38. Rasouli M, Kiasari AM, Mokhberi V: The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Clin Chem Lab Med 2006, 44:1015-1021.
39. de Nigris F, Lerman A, Ignarro LJ, et al.: Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis. Trends Mol Med 2003, 9:351-359.
40. Boden WE, O'Rourke RA, Teo KK, et al.: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007, 356:1503-1516.
41. Kieltyka L, Urbina EM, Tang R, et al.: Framingham risk score is related to carotid artery intima-media thickness in both white and black young adults: the Bogalusa Heart Study. Atherosclerosis 2003, 170:125-130.
42. Kitagawa K, Hougaku H, Yamagami H, et al.: Carotid intima-media thickness and risk of cardiovascular events in high-risk patients. Results of the Osaka Follow-Up Study for Carotid Atherosclerosis 2 (OSACA2 Study). Cerebrovasc Dis 2007, 24:35-42.
43. Greenland P, Bonow RO, Brundage BH, et al.: ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2007, 49:378-402.
44. Ford ES, Ajani UA, Croft JB, et al.: Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med 2007, 356:2388-2398.
45. Williamson DF, Pamuk E, Thun M, et al.: Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 1995, 141:1128-1141.
46. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
47. Covas MI, Nyyssonen K, Poulsen HE, et al.: The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med 2006, 145:333-341.
48. Perez-Martinez P, Lopez-Miranda J, Blanco-Colio L, et al.: The chronic intake of a Mediterranean diet enriched in virgin olive oil, decreases nuclear transcription factor kappaB activation in peripheral blood mononuclear cells from healthy men. Atherosclerosis 2007, 194:e141-e146.
49. de Lorgeril M, Salen P, Martin JL, et al.: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999, 99:779-785.
50. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
51. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419.
52. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
53. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
54. Wolfe ML, Rader DJ: Cholesteryl ester transfer protein and coronary artery disease: an observation with therapeutic implications. Circulation 2004, 110:1338-1340.
55. Tall AR, Yvan-Charvet L, Wang N: The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007, 27:257-260.
56. Bots ML, Visseren FL, Evans GW, et al.: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370:153-160.
57. Buse JB: Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99:S21-S33.
58. US National Institutes of Health: Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. Available at http://clinicaltrials.gov/ct/show/NCT00461630?order=1. Accessed July 2007.
59. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
60. Shah PK, Chyu KY, Fredrikson GN, Nilsson J: Vaccination for atherosclerosis: a novel therapeutic paradigm. Expert Rev Vaccines 2004, 3:711-716.
61. Miller DT, Ridker PM, Libby P, Kwiatkowski DJ: Atherosclerosis: the path from genomics to therapeutics. J Am Coll Cardiol 2007, 49:1589-1599.